Skip to main content

Drug Interactions between nipocalimab and Tice BCG

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

BCG nipocalimab

Applies to: Tice BCG (bcg) and nipocalimab

Consumer information for this interaction is not currently available.

GENERALLY AVOID: The administration of a live, attenuated virus or bacteria as oncolytic immunotherapy during treatment with a neonatal Fc receptor (FcRn) blocker like efgartigimod alfa, rozanolixizumab, or nipocalimab has not been evaluated. FcRn blockers can cause a transient reduction in IgG levels. In addition, efgartigimod alfa may decrease white blood cell, lymphocyte, and neutrophil counts. Administration of medications containing live, attenuated virus or bacteria during treatment with FcRn blockers may theoretically increase the risk of disseminated infection due to enhanced replication of virus or bacteria in the presence of diminished immune competence. Increased adverse reactions and decreased or suboptimal therapeutic response to the immunotherapy may also occur.

MANAGEMENT: Until more information is available, it may be advisable to avoid the concomitant use of FcRn blockers with oncolytic immunotherapy such as talimogene laherparepvec and the BCG strain of Mycobacterium bovis.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer